Firms to work together on superbugs in China

23 October 2019
2019_biotech_production_bottles_big

Californian infectious disease specialist Qpex Biopharma has entered into a multi-product collaboration with Shanghai’s Brii Biosciences.

The firms will work together to develop and commercialize Qpex's portfolio in China of potentially best-in-class therapies to treat a range of multi-drug resistant gram-negative infections.

Brii was launched in 2018 with around $260 million in financial backing. The company aims to accelerate the development and delivery of breakthrough drugs in China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology